Gemtuzumab the conjugate represents a significant advance in the approach of acute leukemic cancer, mainly severe leukemic malignancy (AML). The agent pairs a targeted immunoglobulin targeting against the CD33 antigen https://www.targetmol.com/compound/gemtuzumab